A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Official Title

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Summary:

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Trial Description

Primary Outcome:

  • Progression free survival (PFS) by Blinded Independent Central Review (BICR)
Secondary Outcome:
  • Progression Free Survival (PFS) by Investigator Assessment
  • Progression Free Survival Rate (PFSR)
  • Objective response rate (ORR)
  • Duration of response (DOR)
  • Overall Survival (OS)
  • Overall survival rate (OSR)
  • Incidence of Adverse Events (AE)
  • Incidence of Serious Adverse Events (SAE)
  • Incidence of Adverse Events (AE) leading to discontinuation
  • Incidence of death
  • Number of clinically significant changes in lab assessment: Blood
  • Number of clinically significant changes in lab assessment: Blood Serum
  • Number of clinically significant changes in lab assessment: Urine

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society